Ligand validation:3LXA

GLA: alpha-D-galactopyranose

GLA is a Ligand Of Interest in 3LXA designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
3LXA_GLA_A_801	62%	62%	0.168	0.96	0.39	1.04	-	1	2	0	100%	1
3LXA_GLA_B_802	48%	60%	0.183	0.928	0.64	0.89	-	-	0	0	100%	1
3LXA_GLA_A_803	5%	48%	0.392	0.811	0.82	1.16	-	1	0	0	100%	1
3LXA_GLA_B_804	3%	59%	0.508	0.854	0.61	0.96	-	1	1	0	100%	1
3HG5_GLA_A_801	85%	59%	0.087	0.951	0.53	1.03	-	1	0	0	100%	1
3GXP_GLA_A_3681	55%	20%	0.118	0.886	1.39	1.96	1	7	0	0	100%	1
5ELB_GLA_C_203	100%	67%	0.041	0.992	0.43	0.83	-	-	0	0	100%	0.4
5DNF_GLA_I_101	99%	45%	0.053	0.991	0.91	1.22	-	1	0	0	100%	0.9167
1DJR_GLA_F_1304	99%	44%	0.049	0.984	0.85	1.31	-	2	0	0	100%	1
4R6Q_GLA_G_202	99%	38%	0.053	0.983	1.33	1.09	2	2	0	0	100%	1
7JW4_GLA_A_701	99%	52%	0.055	0.984	1.08	0.79	1	-	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.